With the exception of few publications reporting a putative protective role in tumour progression [172–175], a consistent number of proteomic studies have identified LRG1 as a valuable biomarker for the diagnosis and clinical assessment of a variety of cancer types (Table 1). This evidence concerns the gene LRG1 and cancer.